| Authors: |
Morganti S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Broad Institute of MIT and Harvard, Cambridge, MA, United States., Kim SE; Data Science, Dana-Farber Cancer Institute, Boston, MA, United States., Jin Q; Data Science, Dana-Farber Cancer Institute, Boston, MA, United States., Cha J; Harvard Medical School, Boston, MA, United States., Zeigler JE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States., Newman AB; Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States., Kirkner GJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States., Snow C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States., Zheng Y; Data Science, Dana-Farber Cancer Institute, Boston, MA, United States., Vincuilla J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, United States., Parker T; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, United States., Buehler RM; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, United States., Bychkovsky BL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, United States., Dibble KE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Sella T; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Ruddy KJ; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Rosenberg SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Collins LC; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, United States., Peppercorn J; Harvard Medical School, Boston, MA, United States.; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, United States., Schapira L; Division of Medical Oncology, Department of Medicine, Stanford Cancer Institute, Palo Alto, CA, United States., Borges VF; Division of Medical Oncology, Department of Medicine, University of Colorado, Denver, CO, United States., Guzman-Arocho YD; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States., Come SE; Harvard Medical School, Boston, MA, United States.; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, United States., Warner E; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Poorvu PD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Lambertini M; Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genova, Italy.; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genoa, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy., Hughes ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, United States., King TA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, United States., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Garber JE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States., Tayob N; Harvard Medical School, Boston, MA, United States.; Broad Institute of MIT and Harvard, Cambridge, MA, United States., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Lynce F; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States. |
